JP2002193825A - Liquid composition - Google Patents
Liquid compositionInfo
- Publication number
- JP2002193825A JP2002193825A JP2000399794A JP2000399794A JP2002193825A JP 2002193825 A JP2002193825 A JP 2002193825A JP 2000399794 A JP2000399794 A JP 2000399794A JP 2000399794 A JP2000399794 A JP 2000399794A JP 2002193825 A JP2002193825 A JP 2002193825A
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- extract
- polyoxyethylene
- fatty acid
- ginsenosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- -1 fatty acid ester Chemical class 0.000 claims abstract description 34
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 18
- 229930195729 fatty acid Natural products 0.000 claims abstract description 18
- 239000000194 fatty acid Substances 0.000 claims abstract description 18
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 13
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 241000208340 Araliaceae Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 229920000223 polyglycerol Polymers 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 244000000626 Daucus carota Species 0.000 description 7
- 235000002767 Daucus carota Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 4
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 229940098465 tincture Drugs 0.000 description 4
- 229940008396 carrot extract Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- DNZGTMUOLYMUKJ-UHFFFAOYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCC(O)=O DNZGTMUOLYMUKJ-UHFFFAOYSA-N 0.000 description 1
- MMQZBEXYFLXHEN-UHFFFAOYSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O MMQZBEXYFLXHEN-UHFFFAOYSA-N 0.000 description 1
- WTAYIFXKJBMZLY-XZABIIKCSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O WTAYIFXKJBMZLY-XZABIIKCSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 101100219325 Phaseolus vulgaris BA13 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229940026310 caffeine 50 mg Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- SELHWUUCTWVZOV-UHFFFAOYSA-N dodecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCCCCCC(O)=O SELHWUUCTWVZOV-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020696 epimedium extract Nutrition 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940046664 taurine 500 mg Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の属する技術分野】本発明はニンジン中の配糖体
であるジンセノサイド類を安定に配合した可溶化液体組
成物に関する。TECHNICAL FIELD The present invention relates to a solubilized liquid composition in which ginsenosides, which are glycosides in carrots, are stably mixed.
【従来の技術】ジンセノサイド類は、単独あるいは他の
成分との相互作用により、種々の薬理作用を発揮する。
そのため、滋養強壮、疲労回復等を目的とした液剤中に
多く配合されている。しかし、このようなジンセノサイ
ド類は、水溶液中、特に酸性領域において、非常に分解
しやすいといった問題があった。そのため、ニンジン中
のジンセノサイド類を水溶液中でも安定化する方法が望
まれていた。2. Description of the Related Art Ginsenosides exert various pharmacological actions by themselves or by interaction with other components.
Therefore, it is often blended in liquids for nutritional tonicity, recovery from fatigue, and the like. However, such ginsenosides have a problem that they are very easily decomposed in an aqueous solution, particularly in an acidic region. Therefore, a method for stabilizing ginsenosides in a carrot even in an aqueous solution has been desired.
【発明が解決しようとする課題】本発明の目的は、ジン
セノサイド類を経時的にも安定に配合した可溶化液体組
成物を提供することにある。SUMMARY OF THE INVENTION An object of the present invention is to provide a solubilized liquid composition containing ginsenosides stably over time.
【課題を解決するための手段】ジンセノサイド類を安定
化する検討を重ねたところ、ジンセノサイド類を含有す
る液体組成物にポリグリセリン脂肪酸エステルを配合す
ると、ジンセノサイド類は溶解する。しかし、ポリグリ
セリン脂肪酸エステルは低温保存時、溶解度が低下し、
沈澱や浮遊物を生じ易い。そのため、ポリグリセリン脂
肪酸エステルを単独で可溶化液体組成物中に配合するこ
とは好ましくない。そこで、ジンセノサイド類及びポリ
グリセリン脂肪酸エステルを配合した可溶化液体組成物
中に、ポリオキシエチレン系非イオン性界面活性剤及び
油成分を配合することにより、外観を損なうことなく、
ジンセノサイド類の成分低下を防ぎ、安定化できること
を見出した。すなわち、本発明はポリグリセリン脂肪酸
エステル、ポリオキシエチレン系非イオン性界面活性
剤、油成分を配合したジンセノサイド類含有可溶化液体
組成物である。本発明で使用されるジンセノサイド類は
ニンジンおよびニンジンの抽出物中に存在し、本発明で
は、ニンジンの乾燥粉末、抽出エキス等の形態で用いる
ことができる。また、ジンセノサイド類は、有機合成や
バイオテクノロジーにより合成されたものでもよく、そ
のまま用いてもよい。本発明におけるジンセノサイド類
の液体組成物中への配合量は1.0×10-4〜10w/v%であ
る。本発明において使用されるポリグリセリン脂肪酸エ
ステルはデカグリセリンモノミリスチン酸エステル、ヘ
キサグリセリンモノミリスチン酸エステル、デカグリセ
リンモノラウリン酸エステル、ヘキサグリセリンモノラ
ウリン酸エステル、デカグリセリンモノステアリン酸エ
ステル、ヘキサグリセリンモノステアリン酸エステル、
デカグリセンモノカプリル酸エステル、デカグリセリン
モノオレイン酸エステル、ヘキサグリセリンモノオレイ
ン酸エステル、デカグリセリンモノリノレン酸エステル
等が好ましく、これらを1種あるいは2種以上配合する
ことができる。その中でもデカグリセリンモノミリスチ
ン酸エステル、デカグリセリンモノステアリン酸エステ
ル、デカグリセリンモノラウリン酸エステルが特に好ま
しい。例えば、日光ケミカルズ株式会社製Decaglyn 1-
L、Decaglyn 1-M、Decaglyn 1-S、Decaglyn 1-50VS、太
陽化学株式会社製 Q-14S及び阪本薬品 ML-750等が挙げ
られる。ポリグリセリン脂肪酸エステルの量は、ジンセ
ノサイド類1重量部に対して1重量〜1000重量部で
ある。本発明において使用されるポリオキシエチレン系
非イオン性界面活性剤としては、例えばポリオキシエチ
レン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪
酸エステル、ポリエチレングリコール脂肪酸エステル、
ポリオキシエチレングリセリン脂肪酸エステル等が挙げ
られる。またポリオキシエチレン系界面活性剤の配合量
はポリグリセリン脂肪酸エステル1重量部に対して、1/
6〜1重量部である。本発明において使用される油成分
としては、ビタミンE及びその誘導体、ビタミンA、ビ
タミンD、ビタミンK、γ−オリザノール及び、大豆
油、中鎖脂肪酸トリグリセリド、γ−リノレン酸等のト
リグリセリン脂肪酸エステルなどが挙げられる。また、
油成分の配合量はポリグリセリン脂肪酸エステル1重量
部に対して1×10-2〜1重量部である。本発明では生薬
抽出物由来の沈殿の抑制を目的として、ポリビニルピロ
リドン、ポリオキシエチレンポリオキシプロピレングリ
コール、ポリビニルアルコール等の高分子物質を配合す
ることができ、その中でもポリビニルピロリドン、ポリ
オキシエチレンポリオキシプロピレングリコールが特に
好ましい。本発明では乳糖、ショ糖、果糖、ブドウ糖、
ソルビト−ル、マルチトール、エリスリトール、キシリ
トール、トレハロース、ステビア抽出物等を甘味剤また
はエネルギー源として配合することができる。本発明の
可溶化液体組成物のpHは特に限定がないが、飲料とし
たときの防腐性、風味等をも考慮すれば、本発明の可溶
化液体組成物のpHは2.5〜7、好ましくはpH3〜6程
度である。また、その他の成分として、油成分でないビ
タミン類、ミネラル類、アミノ酸およびその塩類、生薬
および生薬抽出物、ローヤルゼリー、カフェイン、コン
ドロイチン硫酸ナトリウムなどを本発明の効果を損なわ
ない範囲で配合することができる。また、必要に応じて
他の公知の添加剤、例えば、抗酸化剤、着色剤、香料、
矯味剤、保存料、pH調整剤などの製剤技術一般に使用
される物質を配合することができ、常法により、シロッ
プ剤、液剤などの経口製剤とすることができる。またポ
リグリセリン脂肪酸エステル、ポリオキシエチレン系界
面活性剤以外の界面活性剤などを溶解補助剤として本発
明の効果を損なわない範囲内で配合してもよい。また、
グリセリン、ジグリセリン等の水溶性多価アルコール等
を溶解補助剤として配合してもよい。pH調整剤として
は、たとえば、乳酸、クエン酸、リンゴ酸、コハク酸、
フマル酸、酒石酸、リン酸およびそれらの塩が挙げられ
る。これらのpH調整剤を単独または複数組み合わせるこ
とができる。Investigations for stabilizing ginsenosides have been repeated. When a polyglycerin fatty acid ester is added to a liquid composition containing ginsenosides, the ginsenosides are dissolved. However, the solubility of polyglycerin fatty acid esters decreases when stored at low temperatures,
Precipitates and floats easily occur. Therefore, it is not preferable to mix the polyglycerin fatty acid ester alone in the solubilized liquid composition. Therefore, by blending a polyoxyethylene-based nonionic surfactant and an oil component in a solubilized liquid composition containing ginsenosides and polyglycerin fatty acid ester, without impairing the appearance,
It has been found that the components of ginsenosides can be prevented from lowering and can be stabilized. That is, the present invention is a ginsenoside-containing solubilized liquid composition containing a polyglycerin fatty acid ester, a polyoxyethylene-based nonionic surfactant, and an oil component. The ginsenosides used in the present invention are present in carrots and carrot extracts, and in the present invention, they can be used in the form of carrot dry powder, extracted extract and the like. Ginsenosides may be those synthesized by organic synthesis or biotechnology, or may be used as they are. The amount of ginsenosides in the present invention in the liquid composition is 1.0 × 10 −4 to 10 w / v%. Polyglycerin fatty acid ester used in the present invention is decaglycerin monomyristate, hexaglycerin monomyristate, decaglycerin monolaurate, hexaglycerin monolaurate, decaglycerin monostearate, hexaglycerin monostearate ,
Preferred are decaglycene monocaprylate, decaglycerin monooleate, hexaglycerin monooleate, decaglycerin monolinolenate and the like, and one or more of these may be blended. Among them, decaglycerin monomyristate, decaglycerin monostearate, and decaglycerin monolaurate are particularly preferred. For example, Decaglyn 1- made by Nikko Chemicals Co., Ltd.
L, Decaglyn 1-M, Decaglyn 1-S, Decaglyn 1-50VS, Q-14S manufactured by Taiyo Kagaku Co., Ltd. and Sakamoto Chemical ML-750. The amount of the polyglycerin fatty acid ester is 1 to 1000 parts by weight based on 1 part by weight of ginsenosides. Examples of the polyoxyethylene-based nonionic surfactant used in the present invention include polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyethylene glycol fatty acid ester,
And polyoxyethylene glycerin fatty acid esters. The amount of the polyoxyethylene surfactant is 1 / part by weight of the polyglycerin fatty acid ester.
6 to 1 part by weight. Examples of the oil component used in the present invention include vitamin E and its derivatives, vitamin A, vitamin D, vitamin K, γ-oryzanol, and soybean oil, medium-chain fatty acid triglycerides, and triglycerin fatty acid esters such as γ-linolenic acid. Is mentioned. Also,
The amount of the oil component is 1 × 10 -2 to 1 part by weight based on 1 part by weight of the polyglycerin fatty acid ester. In the present invention, for the purpose of suppressing precipitation derived from a crude drug extract, a polymer substance such as polyvinylpyrrolidone, polyoxyethylene polyoxypropylene glycol, or polyvinyl alcohol can be blended. Among them, polyvinylpyrrolidone, polyoxyethylene polyoxy Propylene glycol is particularly preferred. In the present invention, lactose, sucrose, fructose, glucose,
Sorbitol, maltitol, erythritol, xylitol, trehalose, stevia extract and the like can be blended as a sweetener or energy source. Although the pH of the solubilized liquid composition of the present invention is not particularly limited, the pH of the solubilized liquid composition of the present invention is 2.5 to 7, preferably, in consideration of the preservability and flavor of a beverage. The pH is about 3 to 6. Further, as other components, vitamins, minerals, amino acids and salts thereof, non-oil components, crude drugs and crude drug extracts, royal jelly, caffeine, sodium chondroitin sulfate, etc. may be blended within a range that does not impair the effects of the present invention. it can. Also, if necessary, other known additives, for example, antioxidants, coloring agents, fragrances,
Substances generally used in pharmaceutical technology such as flavoring agents, preservatives, and pH adjusters can be blended, and oral preparations such as syrups and liquids can be prepared by a conventional method. Further, a surfactant other than polyglycerin fatty acid ester and polyoxyethylene-based surfactant may be added as a solubilizing agent within a range that does not impair the effects of the present invention. Also,
A water-soluble polyhydric alcohol such as glycerin or diglycerin may be blended as a solubilizer. Examples of pH adjusters include lactic acid, citric acid, malic acid, succinic acid,
Fumaric acid, tartaric acid, phosphoric acid and salts thereof. These pH adjusters can be used alone or in combination.
【本発明の効果】本発明において、ポリグリセリン脂肪
酸エステルはニンジン中のジンセノサイドが液体組成物
中で分解するのを抑制し、ポリオキシエチレン系界面活
性剤及び油成分はポリグリセリン脂肪酸エステルの低温
での浮遊物の生成を抑制する。そのため、本発明によ
り、外観を損なうことなく、ジンセノサイド類を安定に
含有する可溶化液体組成物が提供できる。According to the present invention, the polyglycerin fatty acid ester suppresses the decomposition of ginsenoside in carrot in the liquid composition, and the polyoxyethylene surfactant and the oil component are formed at a low temperature of the polyglycerin fatty acid ester. Suppress the formation of suspended matter. Therefore, according to the present invention, a solubilized liquid composition containing ginsenosides stably can be provided without impairing the appearance.
【実施例】次に、本発明を実施例および比較例により更
に詳細に説明するが、本発明はこれらの記載に限定され
るものではない。Next, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to these descriptions.
【0001】実施例1 表1に示す各種界面活性剤及びグリセリン、大豆油を80
℃にて加温混合した後、80℃温水により溶解した。これ
らの水溶液に、ニンジンエキスを0.18w/v%(ジンセノサ
イドRb1濃度として9.0×10-3w/v%)、ポリビニルピ
ロリドン0.3w/v%、クエン酸 1.0w/v%を配合し、1M-NaOH
によりpHを4.6に調整した。これらをガラス瓶に充填
し、キャップを施し、実施例1とした。Example 1 Various surfactants, glycerin and soybean oil shown in Table 1 were mixed with 80
After heating and mixing at 80 ° C., the mixture was dissolved in hot water at 80 ° C. To these aqueous solutions, 0.18 w / v% of carrot extract (9.0 × 10 −3 w / v% as ginsenoside Rb1 concentration), 0.3 w / v% of polyvinylpyrrolidone and 1.0 w / v% of citric acid were mixed, and 1M- NaOH
Adjusted the pH to 4.6. These were filled in a glass bottle, and a cap was provided.
【0002】比較例 表1に示す各種界面活性剤及びグリセリン、大豆油を80
℃にて加温混合した後、80℃温水により溶解した。これ
らの水溶液に、ニンジンエキスを0.18w/v%(ジンセノサ
イドRb1濃度として9.0×10-3w/v%)、ポリビニルピ
ロリドン0.3w/v%、クエン酸 1.0w/v%を配合し、1M-NaOH
によりpHを4.6に調整した。これらをガラス瓶に充填
し、キャップを施し、比較例1〜3とした。Comparative Examples Various surfactants, glycerin and soybean oil shown in Table 1 were
After heating and mixing at 80 ° C., the mixture was dissolved in hot water at 80 ° C. To these aqueous solutions, 0.18 w / v% of carrot extract (9.0 × 10 −3 w / v% as ginsenoside Rb1 concentration), 0.3 w / v% of polyvinylpyrrolidone and 1.0 w / v% of citric acid were mixed, and 1M- NaOH
Adjusted the pH to 4.6. These were filled in a glass bottle and capped, and Comparative Examples 1 to 3 were obtained.
【表1】 [Table 1]
【0003】(評価方法)実施例1、比較例で得た本発
明の液体組成物を65℃恒温槽にて5日間保管後、液体組
成物中のジンセノサイドRb1含量を液体クロマトグラフ
法により定量した。その結果を、調製直後のジンセノサ
イドRb1含量に対する65℃、5日間後の残存率(%)と
して示した。また、5℃恒温槽にて1ヶ月保管後、内容液
中の沈殿及び浮遊物を目視により観察した。沈殿及び浮
遊物の程度は、表2に示す基準により判定した。これら
の実験の結果を表3に示した.(Evaluation method) After the liquid compositions of the present invention obtained in Example 1 and Comparative Example were stored in a thermostat at 65 ° C. for 5 days, the content of ginsenoside Rb1 in the liquid compositions was quantified by liquid chromatography. . The results are shown as the residual ratio (%) after 5 days at 65 ° C. with respect to the ginsenoside Rb1 content immediately after preparation. After storage in a thermostat at 5 ° C. for one month, precipitates and suspended matter in the content liquid were visually observed. The degree of precipitation and suspended matter was determined according to the criteria shown in Table 2. Table 3 shows the results of these experiments.
【表2】 [Table 2]
【表3】 [Table 3]
【0004】本発明により、外観を損なうことなく、液
体組成物中でもニンジン由来のジンセノサイド類の分解
を防ぎ、ジンセノサイド類を安定化することができた。According to the present invention, ginsenosides derived from carrots can be prevented from being decomposed even in a liquid composition and the ginsenosides can be stabilized without impairing the appearance.
【0005】実施例2 シャクヤクエキス 30mg(原生薬換算120mg) ニンジンエキス(含ジンセノサイド類4.5mg)90mg(600) オウギリュウエキス 0.3mL(300) カンゾウエキス 50mg(200) ジオウエキス 300mg(300) トウキリュウエキス 0.4mL(400) ロクジョウチンキ 1.08mL(300) イカリソウエキス 100mg(1000) ショウキョウチンキ 0.6mL(120) ケイヒリュウエキス 0.3mL(300) ヨクイニンリュウエキス 0.6mL(600) ハンピチンキ 1.25mL(250) ブクリョウエキス 9.6mg(300) タイソウナンエキス 70mg(230) サンヤクリュウエキス 0.3mL(300) トシシエキス 33mg(300) トチュウチュウシュツエキ 0.3mL(300) カイクジンチンキ 500mg(100) オンジエキス 15mg(150) サンシュユリュウエキス 0.5mL(500) ムイラプアマエキス 15mg(300) オウセイリュウエキス 0.6mL(600) クコシリュウエキス 0.3mL(300) サイコリュウエキス 0.15mL(150) ゴミシリュウエキス 0.3mL(300) トウチュウカソウリュウエキス 0.3mL(300) VB1 10mg VB2 5mg VB6 5mg カフェイン 50mg タウリン 500mgホ゜リオキシエチレン 硬化ヒマシ油 100mgテ゛カク゛リセリンモノミリスチン 酸エステル 100mgテ゛カク゛リセリンモノステアリン 酸エステル 100mg 大豆油 30mg ポリビニルピロリドン 300mgホ゜リオキシエチレンホ゜リオキシヒ゜ロヒ゜レンク゛リコール 300mg キシリトール 5000mg 白糖 5000mg ステビア抽出物 5mg クエン酸 適量 DL−リンゴ酸ナトリウム 200mg パラオキシ安息香酸プロピル 3.3mg パラオキシ安息香酸ブチル 3.3mg 安息香酸ナトリウム 3mg ミックスフルーツフレーバー 50mg 精製水 適量 上記の各成分を精製水に攪拌溶解し、全量を50mLと
し、安定なジンセノサイド類含有製剤を得た(pH4.
5)。Example 2 Peony extract 30 mg (120 mg in terms of crude drug) Carrot extract (4.5 mg of ginsenosides) 90 mg (600) Ogi-ryu extract 0.3 mL (300) Licorice extract 50 mg (200) Geo extract 300 mg (300) Touki Ryu extract 0.4 mL (400) Liqueur tincture 1.08 mL (300) Epimedium extract 100 mg (1000) Ginger tincture 0.6 mL (120) Cauliflower extract 0.3 mL (300) Yokuininru extract 0.6 mL (600) Hampit tincture 1.25 mL (250) Bakryou extract 9.6 mg (300) Taisounan extract 70 mg (230) Sanya cryu extract 0.3 mL (300) Toshishi extract 33 mg (300) 0.3 mL (300) Calyx tincture 500 mg (100) Onji extract 15 mg (150) Sanjuryu extract 0.5 mL (500) Muirapuama extract 15 mg (300) Oysteryll extract 0.6 mL (600) Silkworm extract 0.3 mL (300) Psycho-Ryu extract 0.15 mL (150) Gourmet Ryu extract 0.3 mL (300) Eucommia biloba extract 0.3 mL (300) VB1 10 mg VB2 5 mg VB6 5 mg Caffeine 50 mg Taurine 500 mg Polyoxyethylene hydrogenated castor oil 100 mg Ester 100mg Decaglycerin monostearate 100mg Soybean oil 30mg Polyvinylpyrrolidone 300mg Polyoxyethylene Reoxyhydroperylene glycol 300 mg Xylitol 5000 mg Sucrose 5000 mg Stevia extract 5 mg Citric acid proper amount DL-Sodium malate 200 mg Propyl parahydroxybenzoate 3.3 mg Butyl paraoxybenzoate 3.3 mg Sodium benzoate 3 mg Suitable amount of mixed fruit flavor 50 mg Each component was stirred and dissolved in purified water to make the total volume 50 mL, thereby obtaining a stable ginsenoside-containing preparation (pH 4.
5).
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 1/14 A61P 1/14 43/00 107 43/00 107 Fターム(参考) 4C076 AA12 AA16 BB01 CC40 DD08E DD30Z DD38 DD43Z DD46 EE16 EE23 FF15 FF16 FF43 GG46 4C088 AB18 AC11 BA08 BA13 CA03 MA03 MA04 MA17 MA52 NA03 ZA66 ZB21 ZC01 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (reference) A61P 1/14 A61P 1/14 43/00 107 43/00 107 F term (reference) 4C076 AA12 AA16 BB01 CC40 DD08E DD30Z DD38 DD43Z DD46 EE16 EE23 FF15 FF16 FF43 GG46 4C088 AB18 AC11 BA08 BA13 CA03 MA03 MA04 MA17 MA52 NA03 ZA66 ZB21 ZC01
Claims (3)
酸エステル、ポリオキシエチレン系非イオン性界面活性
剤および油成分を含有することを特徴とする可溶化液体
組成物1. A solubilized liquid composition comprising ginsenosides, polyglycerin fatty acid ester, a polyoxyethylene nonionic surfactant and an oil component.
性剤がポリオキシエチレン硬化ヒマシ油である請求項1
記載の可溶化液体組成物2. The polyoxyethylene-based nonionic surfactant is polyoxyethylene hydrogenated castor oil.
A solubilized liquid composition as described
エチレンポリオキシプロピレングリコールを配合した請
求項1又は2に記載の可溶化液体組成物3. The solubilized liquid composition according to claim 1, wherein polyvinyl pyrrolidone or polyoxyethylene polyoxypropylene glycol is blended.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000399794A JP4872153B2 (en) | 2000-12-28 | 2000-12-28 | Liquid composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000399794A JP4872153B2 (en) | 2000-12-28 | 2000-12-28 | Liquid composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002193825A true JP2002193825A (en) | 2002-07-10 |
JP4872153B2 JP4872153B2 (en) | 2012-02-08 |
Family
ID=18864505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000399794A Expired - Fee Related JP4872153B2 (en) | 2000-12-28 | 2000-12-28 | Liquid composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4872153B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005298510A (en) * | 2004-04-14 | 2005-10-27 | Amorepacific Corp | Polymer capsule containing ginsenoside, method for producing the same and cosmetic composition containing the same |
EP1878445A1 (en) * | 2005-04-19 | 2008-01-16 | Shanghai Tianbo Biotechnology Co., Ltd. | A method, formulation and use thereor with improved oral absorption of drugs or nutrients |
JP2008120748A (en) * | 2006-11-14 | 2008-05-29 | Taisho Pharmaceutical Co Ltd | gamma-ORYZANOL-SOLUBILIZED LIQUID COMPOSITION |
KR100835864B1 (en) * | 2002-05-27 | 2008-06-09 | (주)아모레퍼시픽 | Nanoemulsion comprising metabolites of ginseng saponin as effective component and preparation method, and skin care compositions for antiaging agent utilizing thereof |
WO2011043455A1 (en) * | 2009-10-09 | 2011-04-14 | エスエス製薬株式会社 | Orally administrable liquid formulation containing acetaminophen |
JP2021524259A (en) * | 2018-05-25 | 2021-09-13 | クヴェッラ コーポレーション | Methods and Compositions for Selective Lysis of Blood Cells and Separation of Microbial Cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04282303A (en) * | 1991-03-08 | 1992-10-07 | Lion Corp | Semi-transparent cosmetics |
JP2000157168A (en) * | 1998-04-01 | 2000-06-13 | Nisshin Oil Mills Ltd:The | Oily composition and its production |
JP2000247890A (en) * | 1999-02-25 | 2000-09-12 | Taisho Pharmaceut Co Ltd | Liquid composition containing paeonflorin |
JP2000290186A (en) * | 1999-04-01 | 2000-10-17 | Taisho Pharmaceut Co Ltd | Liquid composition |
-
2000
- 2000-12-28 JP JP2000399794A patent/JP4872153B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04282303A (en) * | 1991-03-08 | 1992-10-07 | Lion Corp | Semi-transparent cosmetics |
JP2000157168A (en) * | 1998-04-01 | 2000-06-13 | Nisshin Oil Mills Ltd:The | Oily composition and its production |
JP2000247890A (en) * | 1999-02-25 | 2000-09-12 | Taisho Pharmaceut Co Ltd | Liquid composition containing paeonflorin |
JP2000290186A (en) * | 1999-04-01 | 2000-10-17 | Taisho Pharmaceut Co Ltd | Liquid composition |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100835864B1 (en) * | 2002-05-27 | 2008-06-09 | (주)아모레퍼시픽 | Nanoemulsion comprising metabolites of ginseng saponin as effective component and preparation method, and skin care compositions for antiaging agent utilizing thereof |
JP2005298510A (en) * | 2004-04-14 | 2005-10-27 | Amorepacific Corp | Polymer capsule containing ginsenoside, method for producing the same and cosmetic composition containing the same |
EP1878445A1 (en) * | 2005-04-19 | 2008-01-16 | Shanghai Tianbo Biotechnology Co., Ltd. | A method, formulation and use thereor with improved oral absorption of drugs or nutrients |
EP1878445A4 (en) * | 2005-04-19 | 2008-06-25 | Shanghai Tianbo Biotechnology | A method, formulation and use thereor with improved oral absorption of drugs or nutrients |
JP2008120748A (en) * | 2006-11-14 | 2008-05-29 | Taisho Pharmaceutical Co Ltd | gamma-ORYZANOL-SOLUBILIZED LIQUID COMPOSITION |
WO2011043455A1 (en) * | 2009-10-09 | 2011-04-14 | エスエス製薬株式会社 | Orally administrable liquid formulation containing acetaminophen |
JP2021524259A (en) * | 2018-05-25 | 2021-09-13 | クヴェッラ コーポレーション | Methods and Compositions for Selective Lysis of Blood Cells and Separation of Microbial Cells |
Also Published As
Publication number | Publication date |
---|---|
JP4872153B2 (en) | 2012-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102811702B (en) | Liquid oral composition and method for producing same | |
JP4304940B2 (en) | Propolis extract-containing composition for water dispersion and beverage | |
JP4051717B2 (en) | Biotin-containing oral solution | |
JP2001288090A (en) | Minoxidil-containing pharmaceutical preparation | |
JP5839681B2 (en) | Liquid composition containing herbal extract | |
JP2002363105A (en) | Method for masking unpleasant taste and solution for oral administration | |
JP2002193825A (en) | Liquid composition | |
JP2006257010A (en) | WATER-SOLUBLE COMPOSITION OF alpha-LIPOIC ACID, BEVERAGE OR FOOD AND COSMETIC EACH CONTAINING THE SAME COMPOSITION AND METHOD FOR PRODUCING THE SAME COMPOSITION | |
JP2003231647A (en) | Oral liquid composition | |
JP4742289B2 (en) | Solubilized liquid composition with herbal medicine | |
JP2006199631A (en) | Liquid preparation for oral administration excellent in administration feeling | |
JP2003310212A (en) | Composition of water-dispersible or water-soluble leaf extract from lagerstroemia speciosa | |
JP3508314B2 (en) | Liquid formulation containing vitamin C | |
JP4403590B2 (en) | Vitamin B1 combination liquid | |
JP5083492B2 (en) | Liquid for internal use | |
JPH11236330A (en) | Microemulsion containing vitamin ds | |
JP4321193B2 (en) | Carrot combination liquid composition | |
JP4929629B2 (en) | Zinc-containing composition for oral administration | |
JP4857460B2 (en) | Solubilized liquid composition | |
JP4586336B2 (en) | Aqueous solution containing fat-soluble substances | |
JP4759776B2 (en) | Liquid composition | |
JP5303086B2 (en) | Oral solution | |
JP2009106216A (en) | Calcium absorption promoter | |
JPWO2007135774A1 (en) | Herbal medicine-containing oral solution composition | |
JP4789292B2 (en) | Oral solution with improved flavor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071218 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110427 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20111025 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111107 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141202 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4872153 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141202 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |